WWW.IJRPR.COM

International Journal of Research Publication and Reviews

Journal homepage: www.ijrpr.com ISSN 2582-7421

Perspective: Reconsidering the Role of PAR-4 in Vascular Remodeling: A Potential Therapeutic Nexus

Eshiobomhe Sigmus Aimofumhe[1], Winner Igbogobo Armstrong[2]

[1]Department of Life and Physical Sciences, Fisk University, Nashville, Tennessee, USA, 37208
[2]Department of Agricultural, Life and Natural Sciences, Alabama Agricultural and Mechanical University, Huntsville, Alabama, USA, 35801

A B S T R A C T

Cardiovascular disease remains the global leader in mortality, yet the intracellular mechanisms governing vascular remodeling remain underappreciated in therapeutic strategies. Among these mechanisms, protease-activated receptors (PARs), particularly PAR-4, are emerging as overlooked players in the orchestration of vascular smooth muscle cell (VSMC) migration and proliferation. This perspective paper serves as an argument that PAR-4, often viewed as functionally redundant to PAR-1, holds distinct regulatory power over Extracellular-Regulated Kinase (ERK1/2) activation in VSMCs, suggesting a specific and actionable role in vascular disease. In this review paper, we propose a shift in focus towards PAR-4 not just as a redundant receptor but as a central axis in disease progression, with significant therapeutic implications.

Keywords: Cardiovascular, Protease Activated Receptors, Agonist, Receptors, Vascular Smooth Muscle Cells, Analysis, Extracellular-Regulated Kinase

1. Introduction: Vascular Remodeling Is More Than Endothelial

Vascular remodeling is often discussed in terms of inflammation, lipid accumulation, and endothelial dysfunction, but beneath this surface lies a molecular choreography driven by intracellular signals within vascular smooth muscle cells (VSMCs). These cells don't passively respond to injury; they are active agents that migrate, proliferate, and shape the structure of vessels post-injury, whether in atherosclerosis, post-angioplasty restenosis, or hypertension-induced hypertrophy.

Protease-activated receptors (PARs), a family of G-protein-coupled receptors, act as sentinels for extracellular protease activity, translating injury-associated signals like thrombin into intracellular cascades. Yet, the field of cardiovascular proteomics and molecular genetics have historically placed more focus on PAR-1, sidelining PAR-4 despite evidence suggesting its independence and power in modulating downstream ERK signaling pathways. Why?

1.1 The Case for PAR-4: Biochemical Backseat or Central Player?

PAR-1 is often viewed as the "canonical" thrombin receptor, and deservedly so; it's widely expressed and well-characterized. However, in platelets and now increasingly in VSMCs, PAR-4 is emerging not as a backup receptor but as a co-equal or even superior driver of certain intracellular events. Our recent findings add weight to this claim.

In cultured rat aortic VSMCs, we observed robust ERK1/2 phosphorylation upon PAR-4 activation via AY-NH2, a synthetic peptide that mimics its tethered ligand. Interestingly, this phosphorylation was both more sustained and more reproducible than the activation pattern from PAR-1 agonist TFLLR. Even more compelling, this response was abolished by PAR-4 antagonism, showing functional independence.

This is not mere redundancy. It's a receptor with unique kinetic properties and possibly divergent coupling to intracellular G-proteins or scaffolding proteins. The distinct time course of ERK activation implies differential engagement with regulatory kinases or phosphatases. This warrants deeper exploration, not dismissal.

PAR-4 and the ERK Axis: Why It Matters

ERK1/2 is not just another kinase; it's a transcriptional gatekeeper for genes involved in proliferation, migration, and survival. Its activation in VSMCs directly contributes to neointimal hyperplasia, a key driver of restenosis and chronic hypertension. If PAR-4 offers a novel input into this pathway, particularly in the post-injury or pro-thrombotic state, targeting it may selectively suppress the maladaptive remodeling without compromising endothelial healing (a known limitation of some anti-proliferative stents).

More importantly, targeting PAR-4 may avoid the bleeding risk associated with global thrombin inhibition or PAR-1 antagonism. Indeed, platelet-focused studies have already considered PAR-4 inhibition as a safer antithrombotic strategy. Perhaps a similar line of thought could be applied to VSMCs in restenotic or fibrotic vascular beds.

1.2 The Therapeutic Hypothesis: PAR-4 as a Disease-Specific Switch

Could PAR-4 inhibition offer tissue- or disease-specific modulation of vascular remodeling? If future work confirms that PAR-4 is upregulated or functionally primed in pathologic states (e.g., high thrombin burden post-injury), then drugs targeting PAR-4 could selectively attenuate disease processes without harming physiological repair.

This hypothesis raises several compelling avenues:

- Transcriptional control: Is PAR-4 upregulated under pro-inflammatory or high-glucose conditions?
- Spatial specificity: Are VSMCs in large arteries more responsive to PAR-4 than in resistance vessels?
- Therapeutic window: Can PAR-4 antagonism limit remodeling without impeding re-endothelialization?

Current drug development largely ignores PAR-4, likely due to its structural similarity with PAR-1 and assumed redundancy. But redundancy, in biology, often means robustness, and robustness can be exploited pharmacologically.

2. Illustration of Protease Activated Receptors



Fig. 1: Protease-Activated Receptor (PAR) Activation Mechanism and G-Protein Coupling Cascade

This schematic illustrates the canonical activation mechanism of Protease-Activated Receptors (PARs), including PAR-4, which is central to this study. On the left, a protease (e.g., thrombin) cleaves the N-terminal domain of the PAR, exposing a new tethered ligand. This ligand folds back intramolecularly and binds to the body of the receptor, initiating a conformational change.

On the right, this change activates the receptor's associated heterotrimeric G-protein. The GDP bound to the Gα subunit is exchanged for GTP, causing dissociation of the Gα and Gβγ subunits. These free subunits propagate downstream intracellular signals, in this review article, culminating in the phosphorylation of ERK1/2 in vascular smooth muscle cells (VSMCs). The above figure supports the central thesis that PAR-4 has functionally distinct, non-redundant roles in activating ERK signaling, ultimately contributing to the migration and proliferation of VSMCs involved in pathological vascular remodeling.

3. Conclusion: A Call for Reprioritization

It is time to reframe how we view PARs in vascular biology. Rather than seeing PAR-4 as the lesser sibling of PAR-1, we should recognize its potential as a regulatory hub in VSMC-driven vascular remodeling. The data are still emerging, but the narrative is compelling: PAR-4 may not be a backup, but the key switch.

Just as endothelial biology has moved from simplistic models to nuanced understandings of cell-specific and time-dependent signaling, so too should VSMC research embrace the complex interplay of protease receptors and intracellular cascades. The therapeutic potential is vast – but only if we are willing to look beyond the canonical pathways.

References

Evangeline Motley-Johnson, PhD, Meharry Medical College, Nashville, TN, USA

Edelstein LC, Simon LM, Lindsay CR, et al. Common variants in the human platelet PAR4 thrombin receptor alter platelet function and differ by race. Nat Med. 2014;20(12):1609–1616. https://doi.org/10.1038/nm.3712

Coughlin SR. Protease-activated receptors in hemostasis, thrombosis and vascular biology. J Thromb Haemost. 2005;3(8):1800–1814. https://doi.org/10.1111/j.1538-7836.2005.01377.x

Kahn ML, Zheng YW, Huang W, Bigornia V, Zeng D, Moff S, Farese RV Jr, Tam C, Coughlin SR. A dual thrombin receptor system for platelet activation. Nature. 1998;394(6694):690–694. https://doi.org/10.1038/29325

Alexander MR, Owens GK. Epigenetic control of smooth muscle cell differentiation and phenotypic switching in vascular development and disease. Annu Rev Physiol. 2012;74:13–40. https://doi.org/10.1146/annurev-physiol-012110-142315

Johnson GL, Lapadat R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science. 2002;298(5600):1911–1912. https://doi.org/10.1126/science.1072682